These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 16378067)

  • 1. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation.
    Hafiz MM; Faradji RN; Froud T; Pileggi A; Baidal DA; Cure P; Ponte G; Poggioli R; Cornejo A; Messinger S; Ricordi C; Alejandro R
    Transplantation; 2005 Dec; 80(12):1718-28. PubMed ID: 16378067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benefits and risks of solitary islet transplantation for type 1 diabetes using steroid-sparing immunosuppression: the National Institutes of Health experience.
    Hirshberg B; Rother KI; Digon BJ; Lee J; Gaglia JL; Hines K; Read EJ; Chang R; Wood BJ; Harlan DM
    Diabetes Care; 2003 Dec; 26(12):3288-95. PubMed ID: 14633816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events in clinical islet transplantation: one institutional experience.
    Takita M; Matsumoto S; Noguchi H; Shimoda M; Ikemoto T; Chujo D; Tamura Y; Olsen GS; Naziruddin B; Purcell K; Onaca N; Levy MF
    Cell Transplant; 2012; 21(2-3):547-51. PubMed ID: 22793063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience.
    Froud T; Ricordi C; Baidal DA; Hafiz MM; Ponte G; Cure P; Pileggi A; Poggioli R; Ichii H; Khan A; Ferreira JV; Pugliese A; Esquenazi VV; Kenyon NS; Alejandro R
    Am J Transplant; 2005 Aug; 5(8):2037-46. PubMed ID: 15996257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center.
    Goss JA; Schock AP; Brunicardi FC; Goodpastor SE; Garber AJ; Soltes G; Barth M; Froud T; Alejandro R; Ricordi C
    Transplantation; 2002 Dec; 74(12):1761-6. PubMed ID: 12499894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age and Early Graft Function Relate With Risk-Benefit Ratio of Allogenic Islet Transplantation Under Antithymocyte Globulin-Mycophenolate Mofetil-Tacrolimus Immune Suppression.
    Lee D; Keymeulen B; Hilbrands R; Ling Z; Van de Velde U; Jacobs-Tulleneers-Thevissen D; Maleux G; Lapauw B; Crenier L; De Block C; Mathieu C; Pipeleers D; Gillard P
    Transplantation; 2017 Sep; 101(9):2218-2227. PubMed ID: 27779572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.
    Shapiro AM; Lakey JR; Ryan EA; Korbutt GS; Toth E; Warnock GL; Kneteman NM; Rajotte RV
    N Engl J Med; 2000 Jul; 343(4):230-8. PubMed ID: 10911004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.
    Ryan EA; Lakey JR; Rajotte RV; Korbutt GS; Kin T; Imes S; Rabinovitch A; Elliott JF; Bigam D; Kneteman NM; Warnock GL; Larsen I; Shapiro AM
    Diabetes; 2001 Apr; 50(4):710-9. PubMed ID: 11289033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved metabolic control and quality of life in seven patients with type 1 diabetes following islet after kidney transplantation.
    Cure P; Pileggi A; Froud T; Messinger S; Faradji RN; Baidal DA; Cardani R; Curry A; Poggioli R; Pugliese A; Betancourt A; Esquenazi V; Ciancio G; Selvaggi G; Burke GW; Ricordi C; Alejandro R
    Transplantation; 2008 Mar; 85(6):801-12. PubMed ID: 18360260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of cytomegalovirus infections after immunosuppression induction in clinical islet transplantation and impact on graft function.
    Eckhard M; Martin I; Eich T; Weimer R; Zinn S; Bretzel RG; Brendel MD
    Transplant Proc; 2002 Aug; 34(5):1922-4. PubMed ID: 12176630
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient.
    Kaplan B; West P; Neeley H; Martellotto J; Iqbal R; Gangemi A; Hatipoglu B; Benedetti E; Oberholzer J
    Clin Transplant; 2008; 22(2):250-3. PubMed ID: 18339148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes.
    Hering BJ; Kandaswamy R; Ansite JD; Eckman PM; Nakano M; Sawada T; Matsumoto I; Ihm SH; Zhang HJ; Parkey J; Hunter DW; Sutherland DE
    JAMA; 2005 Feb; 293(7):830-5. PubMed ID: 15713772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Achievement of insulin independence via pancreatic islet transplantation using a remote isolation center: a first-year review.
    Barshes NR; Lee T; Goodpasture S; Brunicardi FC; Alejandro R; Ricordi C; Soltes G; Barth M; Hamilton D; Goss JA
    Transplant Proc; 2004 May; 36(4):1127-9. PubMed ID: 15194393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.
    Gillard P; Ling Z; Mathieu C; Crenier L; Lannoo M; Maes B; Roep B; Gorus F; Pipeleers D; Keymeulen B
    Transplantation; 2008 Jan; 85(2):256-63. PubMed ID: 18212631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney function after islet transplant alone in type 1 diabetes: impact of immunosuppressive therapy on progression of diabetic nephropathy.
    Maffi P; Bertuzzi F; De Taddeo F; Magistretti P; Nano R; Fiorina P; Caumo A; Pozzi P; Socci C; Venturini M; del Maschio A; Secchi A
    Diabetes Care; 2007 May; 30(5):1150-5. PubMed ID: 17259471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential kidney/islet transplantation: efficacy and safety assessment of a steroid-free immunosuppression protocol.
    Toso C; Baertschiger R; Morel P; Bosco D; Armanet M; Wojtusciszyn A; Badet L; Philippe J; Becker CD; Hadaya K; Majno P; Bühler L; Berney T;
    Am J Transplant; 2006 May; 6(5 Pt 1):1049-58. PubMed ID: 16611343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes.
    Froud T; Baidal DA; Faradji R; Cure P; Mineo D; Selvaggi G; Kenyon NS; Ricordi C; Alejandro R
    Transplantation; 2008 Dec; 86(12):1695-701. PubMed ID: 19104407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairment of renal function after islet transplant alone or islet-after-kidney transplantation using a sirolimus/tacrolimus-based immunosuppressive regimen.
    Andres A; Toso C; Morel P; Demuylder-Mischler S; Bosco D; Baertschiger R; Pernin N; Bucher P; Majno PE; Bühler LH; Berney T
    Transpl Int; 2005 Nov; 18(11):1226-30. PubMed ID: 16221151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical islet transplantation in type 1 diabetes mellitus: results of Australia's first trial.
    O'Connell PJ; Hawthorne WJ; Holmes-Walker DJ; Nankivell BJ; Gunton JE; Patel AT; Walters SN; Pleass HC; Allen RD; Chapman JR
    Med J Aust; 2006 Mar; 184(5):221-5. PubMed ID: 16515432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression.
    Nanji SA; Shapiro AM
    BioDrugs; 2004; 18(5):315-28. PubMed ID: 15377174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.